Eluvia Is A 'Step Ahead' Of - Not Catching Up To - Rival Peripheral DES, Says BSX
This article was originally published in Clinica
Executive Summary
Peripheral interventions may not be Boston Scientific’s biggest division, but it boasted the highest sales growth among all the other business units in the company’s latest quarterly results. The recent additions to the expanding peripheral interventions portfolio will help maintain this upward trajectory, according to Jane Healy, the recently appointed vice-president of Boston Scientific’s European peripheral interventions unit.